Robert Spomer Joins Moximed as Senior Vice President of Sales
August 20 2024 - 8:00AM
Business Wire
Spomer strengthens commercial expansion with
track record of leading high-growth sales teams
Moximed, an innovative medical device company on a mission to
improve the standard of care for people with knee osteoarthritis
(OA), today announced that Robert Spomer has joined the company as
Senior Vice President of Sales.
“Robert significantly bolsters Moximed’s commercial leadership,”
said Chris Gleason, President and CEO of Moximed. “He’s
successfully built and led sales teams whose introduction of
disruptive technologies transformed the standard of care in
numerous medical fields. Moximed is rapidly investing in and
expanding its commercial infrastructure, and Robert’s leadership
and ability to deploy a winning formula with proven results will be
instrumental as we accelerate adoption of the MISHA® Knee
System.”
Prior to joining Moximed, Spomer served as the Vice President of
Sales at Intrinsic Therapeutics. Spomer previously held sales
leadership roles at multiple disruptive medical technology
companies, including: Stryker, Acclarent (acquired by JNJ), Spirox
(acquired by Entellus), and Neotract (acquired by Teleflex).
“I am thrilled to join Moximed and help fuel the growth of the
business,” said Mr. Spomer. “The MISHA Knee System has the
potential to help millions of symptomatic knee OA patients regain
the active and fulfilling life they deserve. The product has
generated enthusiastic surgeon and patient interest, and I look
forward to our team helping surgeons offer this treatment option
for their patients."
Spomer’s hire is a key role in a rapidly expanding commercial
team as Moximed scales to meet increasing surgeon demand for the
MISHA Knee System. Along with Spomer, recent additions include
sales, reimbursement, and sales support roles as the commercial
infrastructure is built out. Moximed is on pace to double full-time
headcount this year.
About The MISHA® Knee System
Moximed’s MISHA Knee System is for people with medial knee OA
who failed to find relief from previous treatments. These patients
continue to experience pain that interferes with daily activities,
and are ineligible for, or unwilling to undergo, joint replacement
due to age or absence of advanced OA.
Knee OA develops when the joint’s natural shock absorbers,
cartilage and meniscus, no longer cushion the joint from daily
activities, leading to chronic pain and activity limitation. Many
people with mild to moderate OA are otherwise healthy, in their
prime working years, and have busy lives. For these patients, total
knee replacement is a reluctant option, as it is an end-stage
treatment for end-stage disease. OA patients without end-stage
disease seek options that preserve their knee, activity level, and
quality of life.
Reducing weight on painful osteoarthritic joints is known to
reduce pain and improve function. The MISHA Knee System is the
first implantable shock absorber that reduces weight on the knee
joint with every walking step, easing pain, preserving function,
and possibly delaying joint replacement surgery. The implant is
placed on the medial knee and moves with the natural joint,
reducing about 30% of the peak force on the knee with every walking
step.
The MISHA Knee System is FDA cleared.
About Moximed
Moximed’s technology, the MISHA Knee System, is the result of
over a decade of clinical research and development and is the first
implantable shock absorber for the treatment of medial compartment
knee osteoarthritis (OA). With experienced med-tech leadership and
strong investor support, Moximed is poised to elevate the standard
of care and quality of life for millions of pre-arthroplasty knee
OA sufferers hindered by arthritic knee pain and function loss.
Moximed is based in Fremont, California.
To learn more, visit www.moximed.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240820599299/en/
Shay Smith Health+Commerce shay@healthandcommerce.com